Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
-
Bayern boss Kompany out of hospital after meningeal irritation
-
Putin hails Elon Musk as 'truly a genius'
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US stocks eye big tech earnings as Fed holds rates steady
-
Chelsea win as Bayern and Madrid draw in Women's Champions League
-
US Fed holds interest rates steady despite 'too high' inflation
-
Made with munitions from the Falklands War, a 'Chalice of Peace' for the pope
-
Rwanda cannot be blamed for what happens in DR Congo, FM says
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Inter leave it late again in Serie A as Bologna sink AC Milan
-
Italian PM slams 'shameful' release of alleged protest organiser
-
Bolsonaro's escape to the US: How it happened
-
Hollywood producer Kennedy to head LA28 Olympic ceremony plans
-
Russell calls on Scotland to 'kick on' and beat big teams
-
Djokovic wins Basel opener to boost ATP Finals bid
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Cuba wins UN vote against US embargo with weakest backing in 30 years
-
Chiefs sign ex-Ravens kicker suspended over sex allegations
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
Inglis and Carey put Australia in command of South Africa decider
-
From Gaza to Ramallah, Palestinians see little hope in Israeli vote
-
92-year-old US judge handling Maduro case dies
-
US labor leader Dolores Huerta dead: family
-
Perez extends Cadillac deal to 2029
-
Investors turn cautious ahead of tech results, Fed update on rates
-
Arab Israelis proud of high election turnout, uncertain for future
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
Inglis, Carey put Australia in command of South Africa decider
-
Bolsonaro flees Brazil for US after election defeat
-
French firm Safran helps build aircraft wings of the future in UK factory
-
A throne on wheels, popemobiles star in new Vatican show
-
Ceasefire in Russia-occupied Ukrainian city holds for second day
-
Spain high-speed train crash kills 68, injures over 100
-
Canada hikes rates to contain oil price surge caused by Iran war
-
UK woman drugged by husband tells rape trial she woke up bound
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Clean-up starts as Serbian students movement prepares to govern
-
Mona Lisa scrubbed from Syrian textbooks as critics slam conservative drift
-
Flavio Bolsonaro: right-wing heir falls from presidential hopeful to exile
-
Bolsonaro flees Brazil for US after election defeat: AFP
-
UK budget lifts bank tax to offset surging energy bills
-
Brazil's Bolsonaros: between power, prison, and exile
-
Spain high-speed train collision kills 64, injures over 100
-
Israel president urges against new vote despite inconclusive result
-
Brazil's Bolsonaro lands in Florida after election defeat: AFP
-
Eala recovers to move into Tokyo quarter-finals
-
Russia woos African leaders at Moscow summit
-
COPs 'bunch of baloney' says Panama as it vies to host nature summit
-
Local ceasefire in Russia-occupied Ukrainian city holds for second day
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 273453.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53861, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until May 27, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53861.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
J.Williams--AMWN